Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 6Not yet recruiting 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Breast Neoplasms 234Neoplasms 206Carcinoma, Non-Small-Cell Lung 100Colorectal Neoplasms 98Prostatic Neoplasms 93Lung Neoplasms 78Multiple Myeloma 53Melanoma 51Pancreatic Neoplasms 50Head and Neck Neoplasms 49Neoplasm Metastasis 47Leukemia, Myeloid, Acute 43Carcinoma, Hepatocellular 43Ovarian Neoplasms 39Brain Neoplasms 39Squamous Cell Carcinoma of Head and Neck 36Recurrence 35Glioblastoma 33Uterine Cervical Neoplasms 32Sarcoma 30Precursor Cell Lymphoblastic Leukemia-Lymphoma 29Glioma 29Lymphoma, Non-Hodgkin 28Lymphoma 27Colonic Neoplasms 27Stomach Neoplasms 26Carcinoma, Renal Cell 26Lymphoma, Follicular 25Esophageal Neoplasms 24Rectal Neoplasms 23

Interventions

Temozolomide 1Irinotecan 1Cefixime 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Drug-Related Side Effects and Adverse Reactions × 90 days × Clear all
NCT00093353 2026-04-14

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡